Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suryatheja Ananthula

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pharmaceutics|September 7, 2016
An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot SystemsDileep R Janagam, Lizhu Wang, Suryatheja Ananthula, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 27, 2015
Development and validation of sensitive LC/MS/MS method for quantitative bioanalysis of levonorgestrel in rat plasma and application to pharmacokinetics studySuryatheja Ananthula, Dileep R Janagam, Seshulatha Jamalapuram, et al.
European Journal of Medicinal Chemistry|January 1, 2013
Optimization of tocotrienols as antiproliferative and antimigratory leadsFathy A Behery, Mohamed R Akl, Suryatheja Ananthula, et al.
Biofactors (Oxford, England)|June 28, 2013
Potential role of tocotrienols in the treatment and prevention of breast cancerPaul W Sylvester, Mohamed R Akl, Abhita Malaviya, et al.
Advanced Biosystems|July 11, 2020
Injectable In Situ Forming Depot Systems for Long-Acting ContraceptionDileep R Janagam, Suryatheja Ananthula, Kamaljit Chaudhry, et al.
Biomed Research International|August 21, 2014
δ-Tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl2-induced hypoxiaSuryatheja Ananthula, Parash Parajuli, Fathy A Behery, et al.
Anticancer Research|June 13, 2014
Oxazine derivatives of γ- and δ-tocotrienol display enhanced anticancer activity in vivoSuryatheja Ananthula, Parash Parajuli, Fathy A Behery, et al.
Oncotarget|March 19, 2016
Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancersSuryatheja Ananthula, Abhilasha Sinha, Mohamed El Gassim, et al.
The Journal of Allergy and Clinical Immunology|April 8, 2023
Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injurySuryatheja Ananthula, Kirthiram Krishnaveni Sivakumar, Marco Cardone, et al.
The Journal of Clinical Investigation|May 22, 2018
A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivityMarco Cardone, Karla Garcia, Mulualem E Tilahun, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmaceutics|September 7, 2016
An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot SystemsDileep R Janagam, Lizhu Wang, Suryatheja Ananthula, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 27, 2015
Development and validation of sensitive LC/MS/MS method for quantitative bioanalysis of levonorgestrel in rat plasma and application to pharmacokinetics studySuryatheja Ananthula, Dileep R Janagam, Seshulatha Jamalapuram, et al.
European Journal of Medicinal Chemistry|January 1, 2013
Optimization of tocotrienols as antiproliferative and antimigratory leadsFathy A Behery, Mohamed R Akl, Suryatheja Ananthula, et al.
Biofactors (Oxford, England)|June 28, 2013
Potential role of tocotrienols in the treatment and prevention of breast cancerPaul W Sylvester, Mohamed R Akl, Abhita Malaviya, et al.
Advanced Biosystems|July 11, 2020
Injectable In Situ Forming Depot Systems for Long-Acting ContraceptionDileep R Janagam, Suryatheja Ananthula, Kamaljit Chaudhry, et al.
Biomed Research International|August 21, 2014
δ-Tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl2-induced hypoxiaSuryatheja Ananthula, Parash Parajuli, Fathy A Behery, et al.
Anticancer Research|June 13, 2014
Oxazine derivatives of γ- and δ-tocotrienol display enhanced anticancer activity in vivoSuryatheja Ananthula, Parash Parajuli, Fathy A Behery, et al.
Oncotarget|March 19, 2016
Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancersSuryatheja Ananthula, Abhilasha Sinha, Mohamed El Gassim, et al.
The Journal of Allergy and Clinical Immunology|April 8, 2023
Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injurySuryatheja Ananthula, Kirthiram Krishnaveni Sivakumar, Marco Cardone, et al.
The Journal of Clinical Investigation|May 22, 2018
A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivityMarco Cardone, Karla Garcia, Mulualem E Tilahun, et al.
Pageof 2